Cytogen Stock Current Liabilities
| 217330 Stock | KRW 9,220 230.00 2.43% |
Cytogen fundamentals help investors to digest information that contributes to Cytogen's financial success or failures. It also enables traders to predict the movement of Cytogen Stock. The fundamental analysis module provides a way to measure Cytogen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytogen stock.
Cytogen |
Cytogen Company Current Liabilities Analysis
Cytogen's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
In accordance with the recently published financial statements, Cytogen has a Current Liabilities of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. The current liabilities for all Republic of Korea stocks is 100.0% higher than that of the company.
Did you try this?
Run Headlines Timeline Now
Headlines TimelineStay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
| All Next | Launch Module |
Cytogen Fundamentals
| Return On Equity | -96.72 | |||
| Return On Asset | -0.18 | |||
| Operating Margin | (9.92) % | |||
| Current Valuation | 324.23 B | |||
| Shares Outstanding | 5.63 M | |||
| Shares Owned By Insiders | 39.37 % | |||
| Shares Owned By Institutions | 0.05 % | |||
| Price To Sales | 487.61 X | |||
| Revenue | 347.85 M | |||
| Gross Profit | (129.63 M) | |||
| EBITDA | (5.87 B) | |||
| Net Income | (10.87 B) | |||
| Cash And Equivalents | 30.29 B | |||
| Total Debt | 20.9 B | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 16.09 X | |||
| Cash Flow From Operations | (5.23 B) | |||
| Beta | 1.16 | |||
| Market Capitalization | 95.89 B | |||
| Total Asset | 55.53 B | |||
| Z Score | 2.4 | |||
| Net Asset | 55.53 B |
About Cytogen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytogen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytogen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytogen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Cytogen Stock
Cytogen financial ratios help investors to determine whether Cytogen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cytogen with respect to the benefits of owning Cytogen security.